| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,420 |
9,762 |
$116K |
| J0897 |
Injection, denosumab, 1 mg |
491 |
483 |
$68K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
3,430 |
3,021 |
$34K |
| 99215 |
Prolong outpt/office vis |
1,936 |
1,905 |
$31K |
| 20553 |
|
2,098 |
2,038 |
$9K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,350 |
3,236 |
$8K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,333 |
2,934 |
$6K |
| 20610 |
|
2,792 |
1,654 |
$5K |
| J7321 |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
210 |
88 |
$5K |
| 96415 |
|
1,918 |
1,635 |
$5K |
| 96401 |
|
1,198 |
865 |
$3K |
| 20552 |
|
661 |
633 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
427 |
416 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
8,093 |
7,463 |
$1K |
| 73600 |
|
428 |
201 |
$718.32 |
| 73560 |
|
774 |
392 |
$554.46 |
| 73620 |
|
472 |
226 |
$496.83 |
| 72100 |
|
306 |
282 |
$423.68 |
| 73120 |
|
632 |
299 |
$266.22 |
| 73100 |
|
537 |
253 |
$249.16 |
| 72070 |
|
112 |
98 |
$123.19 |
| 71046 |
Radiologic examination, chest; 2 views |
40 |
38 |
$119.20 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,910 |
4,543 |
$55.79 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,372 |
2,311 |
$53.03 |
| 73521 |
|
19 |
18 |
$43.74 |
| 86140 |
|
5,144 |
4,762 |
$42.03 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
3,327 |
2,929 |
$30.49 |
| 77080 |
|
917 |
854 |
$29.67 |
| 72040 |
|
93 |
87 |
$25.20 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
75 |
52 |
$21.96 |
| 85651 |
|
5,290 |
4,889 |
$14.85 |
| 86430 |
|
1,223 |
1,136 |
$7.00 |
| 81002 |
|
2,000 |
1,815 |
$5.84 |
| 86038 |
|
245 |
221 |
$0.00 |
| G9359 |
Documentation of negative or managed positive tb screen with further evidence that tb is not active prior to treatment with a biologic immune response modifier |
613 |
572 |
$0.00 |
| G8399 |
Patient with documented results of a central dual-energy x-ray absorptiometry (dxa) ever being performed |
200 |
198 |
$0.00 |
| 3455F |
|
182 |
176 |
$0.00 |
| 86235 |
|
245 |
221 |
$0.00 |
| J7320 |
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg |
20 |
12 |
$0.00 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
70 |
70 |
$0.00 |
| M1003 |
Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy |
1,086 |
1,011 |
$0.00 |
| 1101F |
|
44 |
34 |
$0.00 |
| 1006F |
|
1,601 |
1,345 |
$0.00 |
| 86063 |
|
75 |
68 |
$0.00 |
| 86225 |
|
245 |
221 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
94 |
50 |
$0.00 |
| G8542 |
Functional outcome assessment using a standardized tool is documented; no functional deficiencies identified, care plan not required |
20 |
14 |
$0.00 |